The E&M "Luca AI Cell Signs MOU with Mongolian Liver Specialist Center for Hepatitis D Diagnosis"

[Asia Economy Reporter Hyunseok Yoo] The E&M's subsidiary, Luka AI Cell (hereinafter Luka), announced on the 22nd that it has signed a Memorandum of Understanding (MOU) related to hepatitis D with the Liver Center owned by the Mongolian Onom Foundation.

According to industry sources, research on hepatitis by domestic companies has been difficult due to the rarity of hepatitis D virus samples. However, with this MOU, Luka expects to securely receive virus samples through the Onom Foundation, enabling verification of the excellence of hepatitis diagnostic technology and in vitro diagnostic kits.

Luka has developed a core technology that uses artificial cell membrane technology to amplify diagnostic signals by about 1,000 times, dramatically improving the sensitivity and specificity of diagnostic kits.

Seunghui Ahn, CEO of Luka, stated, “Mongolia has the highest liver cancer mortality rate in the world, and deaths related to liver diseases account for 15% of all deaths nationwide each year.”

“Through this MOU, we aim to verify our technological capabilities and provide hope to many hepatitis patients in Mongolia from a humanitarian perspective.”

This content was produced with the assistance of AI translation services.